Repare Therapeutics Inc (RPTX) has released an update.
Repare Therapeutics Inc. announced they received a milestone payment from Hoffmann-La Roche Inc. under their 2022 collaboration and license agreement, following the first patient dosing with camonsertib in Roche’s TAPISTRY trial. Details were provided in a press release attached to their Current Report on Form 8-K.
For further insights into RPTX stock, check out TipRanks’ Stock Analysis page.
